Compare Amphastar Pharmaceuticals Inc (AMPH) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Charles Schwab Corporation Common Stock — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.55 (market cap $826.08M), while Charles Schwab Corporation Common Stock trades at $102.66 (market cap $179.34B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 217.1× Amphastar Pharmaceuticals Inc's market cap, and Charles Schwab Corporation Common Stock pays a 1.24% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | SCHW | |
|---|---|---|
Market Cap | $826.08M | $179.34B |
Sector | Health | Financials |
52-Week High | $30.81 | $107.21 |
52-Week Low | $16.87 | $85.35 |
Enterprise Value | $1.22B | — |
Dividend Yield | — | 1.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Charles Schwab (SCHW) trades at $103.12, up 1.19% today, near its pivot point of $102 with bullish technical momentum. The stock shows strong fundamentals with a 37.99% net income margin and 21.79% ROE, supported by three consecutive quarterly earnings beats. Recent news highlights a Zacks upgrade to Strong Buy and a four-year high in the Schwab Trading Activity Index, reflecting robust retail engagement.
Outlook remains positive with a consensus price target of $122.71 implying 19% upside, though overbought RSI signals near-term caution. Risks include interest rate sensitivity and competitive pressures, but institutional bullishness and expanding prediction market initiatives offer growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
